Search for: "Pfizer Inc. v. United States Of America"
Results 41 - 56
of 56
Sorted by Relevance
|
Sort by Date
8 Dec 2007, 11:00 am
(more on the Wahaha v Danone dispute): (China Business Law Blog), What Global Players could learn from Wii v Vii [Nintendo's global new product launch mistakes]: (IPDragon), (China Law Blog), Junk Patents: (China Hearsay),Has your distributor (representative, manufacturer) in China registered your mark? [read post]
15 Mar 2008, 7:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: WIPO Copyright Committee 16th session to discuss Broadcast Treaty, new proposal for exceptions and limitations agreement: (Public Knowledge), (Public Knowledge), (Intellectual Property Watch), (Public Knowledge), (Public Knowledge), (IPwar’s), (Intellectual Property Watch), (KEI), (Public Knowledge), (IP Justice), (IP Justice), (KEI), (KEI),… [read post]
17 Mar 2020, 1:32 pm
Twelve Lots of CHANTIX® (Varenicline) Tablets have been recalled by Pfizer due to N-Nitroso Varenicline content above ADI level. [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO:… [read post]
28 Apr 2011, 3:18 pm
At least the state of the art at the time of the plaintiff’s use applies – unknown and later discovered risks are irrelevant. [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade Representative over… [read post]
28 Mar 2008, 6:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included:Forbes interview with M Meurer (co author of ‘Patent Failure’): (Patent Prospector), (IPBiz), (IPBiz), (IPBiz), (IAM), (Technological Innovation and Intellectual Property), (Patent Prospector),Rambus – Rambus stock soars following jury’s dismissal of antitrust and fraud charges from Hynix, Micron, and Nanya that… [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
15 Feb 2008, 9:00 am
: (Spicy IP),USD 20 billion going off-patent: (Patent Circle),Canadian Prices Review Board asserts jurisdiction over products sold in US, but imported into Canada under Special Access Program: (Gowlings),Canadian Court of Appeal affirms decision allowing patent-owner to be joined to proceedings: Cobalt v Pfizer and Pharmascience v Pfizer: (Gowlings),PharmaStem appeals stem cell patent: asks for greater deference to patent… [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
30 May 2008, 9:09 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: WHO members near accord on global strategy on IP and health: (Intellectual Property Watch), (GenericsWeb), (Gowlings), (IAM), Copiepresse seeks up to €49 million from Google in lawsuit over right to feature links to publishers’ content on internet: (IPKat), (Ars Technica), (Techdirt), (Out-Law), (IP Law360) Singapore ‘image… [read post]
29 Aug 2008, 1:25 pm
– Discussion of IPFrontline.com article ‘Understanding Intellectual Property Value’: (IP finance), How to make sure your IP strategy plan is not doomed to failure: (IP Asset Maximizer Blog) Improve venture capital returns with IP portfolio management: (Ezine @rticles) Global - Trade Marks / Domain Names / Brands Trade mark strategy – counterintuitive names: (IP Thinktank), ICANN Intellectual Property Constituency paper on sunrise mechanisms for… [read post]
13 Jul 2021, 10:58 am
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
15 Mar 2007, 2:12 am
Geographical Distribution of Parties Though the geographical spread of named parties to WIPO UDRP cases (gTLD and ccTLD) reached 137 countries at the end of December 2006, the most frequently named party country both for complainants and for respondents continued to be the United States of America (USA). [read post]
2 Apr 2012, 6:15 am
(In case you’re wondering, the remaining five are Microsoft, Pfizer, Exxon-Mobil, Johnson & Johnson and ADP.) [read post]
